RHLH

recombinant human Luteinizing Hormone, often abbreviated as rhLH, is a biotechnologically produced hormone. It is a synthetic version of luteinizing hormone (LH), a gonadotropic hormone naturally produced by the anterior pituitary gland in both males and females. In the body, LH plays a critical role in reproduction. In women, it triggers ovulation, the release of a mature egg from the ovary, and stimulates the production of progesterone by the corpus luteum. In men, LH stimulates the Leydig cells in the testes to produce testosterone.

rhLH is manufactured using recombinant DNA technology, typically in mammalian cell cultures. This process allows for the production of a highly pure and consistent form of human LH. The primary therapeutic application of rhLH is in assisted reproductive technologies (ART), such as in vitro fertilization (IVF). It is often used in conjunction with recombinant human Follicle-Stimulating Hormone (rhFSH) to stimulate ovarian follicular development and to induce final oocyte maturation and ovulation. This combination helps to ensure that a sufficient number of eggs are retrieved for fertilization. rhLH is also used in cases of hypogonadotropic hypogonadism, a condition where the pituitary gland does not produce enough LH and FSH, leading to impaired reproductive function. The administration of rhLH, alongside FSH, can help to restore fertility in affected individuals.